Ehave Inc Stock Price, News & Analysis

Ehave, Inc. (EHVVF) announces a licensing agreement with Health Wizz to enhance its digital health dashboard by integrating medical records management capabilities. This partnership will enable users to securely share their personal health data while ensuring HIPAA compliance. The Health Wizz mobile app, coupled with blockchain technology, aims to empower individuals to manage their health data efficiently. The global market for Electronic Health Records (EHR) is projected to reach $33.41 billion by 2025, highlighting the significance of this advancement in patient care.

Ehave, Inc. (EHVVF) has launched its KetaDASH subsidiary, introducing a HIPAA-compliant platform for at-home ketamine treatments for anxiety, depression, and PTSD.

The service aims to facilitate access to IV ketamine therapy through partnerships with clinics and healthcare providers. With studies showing that up to 85% of ketamine users experience mental health improvements, this initiative addresses the growing demand for alternative mental health solutions.

CEO Ben Kaplan emphasized the importance of providing compassionate care in a home setting.

Ehave, Inc. (EHVVF) announced the upcoming launch of KetaDASH, a groundbreaking intravenous home delivery service for ketamine therapy, expected to begin by the end of Q2 2021. This platform enables licensed clinics to treat homebound patients, potentially increasing revenue opportunities. The company has secured liability coverage and is negotiating franchising across the U.S.

Ketamine, used for pain relief, is also being studied for depression treatment. KetaDASH offers a personalized approach, connecting patients with skilled nurses for at-home care.

Ehave, Inc. (EHVVF) announced a partnership with Brain Scientific Inc. to conduct brain mapping ketamine clinical trials aimed at treating chronic pain, depression, PTSD, and other mental disorders. The trial will enroll 35 patients and start in the second half of 2021, focusing on establishing a correlation between ketamine treatment and patient improvements. Ehave aims to leverage data and AI for better mental health solutions. The trial’s primary goal is to assess safety and tolerability, with updates promised throughout the clinical process.

Ehave, Inc. (EHVVF) is collaborating with Silo Wellness Inc. for a clinical study on the effects of psilocybin during wellness retreats in Jamaica. This study aims to explore the neurobiological impacts of psychedelic substances on mental health disorders such as depression, anxiety, and ADHD. Utilizing advanced EEG technologies, including Brain Scientific's NeuroCap, Ehave will collect data on brain activity before, during, and after psilocybin administration. This partnership highlights Ehave's commitment to enhancing therapeutic approaches through data-driven insights.

Ehave, Inc. (EHVVF), a provider of digital therapeutics in the psychedelic and mental health sectors, announced that its CEO, Benjamin Kaplan, will appear on the Psychedelic Spotlight segment of New to the Street. The segment will air on NewsMax on March 14th at 10:00 AM EST and on Fox Business on March 15th at 7:30 PM EST. This appearance is an opportunity for shareholders to gain insight into Ehave and the psychedelic sector. Ehave focuses on improving care for brain disorders through innovations like the Ehave Telemetry Portal.

Ehave, Inc. (OTC Pink: EHVVF) has filed a trademark application for its KetaDASH brand with the USPTO, accepted on February 26, 2021. This move aims to protect its brand as the company prepares for beta trials of its ketamine IV therapy in Q2 2021, utilizing advanced vein technology. Ehave has also filed to uplist to the OTCQB. KetaDASH provides a platform for patients to receive supervised ketamine treatment at home, connecting them with skilled nurses.

Ehave, Inc. (EHVVF) has announced plans to launch a beta trial of its innovative KetaDASH ketamine IV therapy in Q2 2021. This platform connects patients with skilled nurses to provide ketamine therapy at home, enhancing patient accessibility and comfort. Ehave has secured liability insurance for its services, eliminating additional costs for clinics. The partnership with Vein-Eye Carry aims to improve IV access success rates, which can fail in up to 40% of critically ill patients. CEO Ben Kaplan emphasizes the urgent need for effective mental health treatments, positioning KetaDASH as a significant advancement.

Ehave, Inc. (EHVVF) announced the upcoming launch of its at-home ketamine delivery platform, KetaDASH, aimed at treating depression rapidly. Ketamine has shown effectiveness for various mental health disorders, with effects often felt within 40 minutes. Ehave leverages its digital therapeutic technology to empower medical practitioners in administering treatments effectively.

The total addressable market for ketamine in depression treatment is estimated at $16.2 billion. Despite recent advancements, KetaDASH is not yet FDA-approved for depression treatments, which presents a potential challenge.